TheEdgeResearch
Home / Stocks / FIFNX

Fidelity Founders Fund (FIFNX)

NASDAQ Financial Services Asset Management
$28.80 ▲ +0.81%
Market Cap
$221.1M
Sector
Financial Services
Industry
Asset Management
Beta
1.29
52-Wk Range
23.81-29.13
CEO
Country
US
Currency
USD

Fidelity Founders Fund operates in the Asset Management industry of the Financial Services sector, headquartered in Boston, MA, US. The stock last traded at $28.80, up 0.81% on the session, giving a market capitalisation of $221.1M. On trailing twelve-month figures it carries a trailing P/E of -14.85, a net margin of -236.6%. Its beta of 1.29 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-14.85
Price / Sales
23.67
Price / Book
1.27
EV / EBITDA
0.00
Gross margin
100.0%
Operating margin
87.1%
Net margin
-236.6%
Return on equity
Debt / equity
0.00
Current ratio
1.22
Dividend yield
2.3%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ
Employees
IPO date
2019-02-22
Headquarters
Boston, MA, US
About Fidelity Founders Fund

This fund primarily allocates its capital to the shares of businesses spearheaded by their original founders. For a company to be classified as 'founder-involved,' at the point of the fund's initial acquisition, one of its founders must hold a significant role either within the senior leadership team or on its board of directors. Investment decisions are shaped by a two-pronged analytical approach: quantitative methods are employed to assess prospects for expansion, intrinsic value, ease of trading, and associated risks. This is complemented by fundamental research, which examines critical elements such as an issuer's financial health, its standing within its sector, and prevailing market and economic climates to make informed selections.

Comparable companies

Fidelity Founders Fund is most often compared with the following Financial Services names:

ADNRXBWLAXCCLAXDNMDXDSCVXLVOLXSKSEX
More research on FIFNX
FIFNX technical analysis FIFNX TheEdge Score Compare against peers
Open full interactive analysis & DCF →